Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response |
| |
Authors: | Yhim Ho-Young Lee Na-Ri Song Eun-Kee Yim Chang-Yeol Jeon So Yeon Shin Seunghwan Kim Jeong-A Kim Hee Sun Cho Eun Hae Kwak Jae-Yong |
| |
Affiliation: | Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Medical School, Deokjin-gu, Jeonju, Republic of Korea. |
| |
Abstract: | The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |